Literature DB >> 12041960

Long-acting progestogens.

Biran Affandi1.   

Abstract

Steroids can be administered in at least five different ways: injectables; hormone-releasing intra-uterine devices (IUDs); implants; vaginal rings; and pills. Progestogens which are synthetic steroids, are used as the main bioactive substances. Different progestogens are effective for different periods of time. Progestins in daily oral pills are effective for 24 hours. The effectiveness of a progestogen can be prolonged by incorporating it in a sustained-release system that gradually releases the hormone; therefore they can be effective up to 5 years or more. Two progestogen-only injectables are widely available in the family planning programmes, (DMPA and NET-EN) and two combined injectables, Cyclofem (DMPA + EC), and Mesigyna (NET-EN + EV). The ring is placed by the woman in her vagina, where it gradually releases hormone. Implantable contraceptives are placed just under the skin on the inside of the woman's arm. Implant capsules release the progestogen at a slow, steady rate. There are three implantables available in the market: Implanon; Norplant; and Jadelle. They are effective for 1-5 years, but then must be replaced. Natural and synthetic progestogens were first added to IUDs in the early 1970s. The main problem of long-acting progestogens is the disruption of the menstrual cycle. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12041960     DOI: 10.1053/beog.2002.0268

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  3 in total

1.  Long-acting progestin-only contraceptives impair endometrial vasculature by inhibiting uterine vascular smooth muscle cell survival.

Authors:  Umit A Kayisli; Murat Basar; Ozlem Guzeloglu-Kayisli; Nihan Semerci; Helen C Atkinson; John Shapiro; Taryn Summerfield; S Joseph Huang; Katja Prelle; Frederick Schatz; Charles J Lockwood
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

2.  Medroxyprogesterone Acetate Decreases Th1, Th17, and Increases Th22 Responses via AHR Signaling Which Could Affect Susceptibility to Infections and Inflammatory Disease.

Authors:  Marie-Pierre Piccinni; Letizia Lombardelli; Federica Logiodice; Ornela Kullolli; Enrico Maggi; Marylynn S Barkley
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

3.  A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD.

Authors:  Nahid Fathizadeh; Fatemeh Abdi; Mitra Savabi
Journal:  Iran J Nurs Midwifery Res       Date:  2011
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.